Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 222

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples

Open access
Trabucco, Sally E., Gowen, Kyle, Maund, Sophia L., Sanford, Eric, Fabrizio, David A., Hall, Michael J., Yakirevich, Evgeny, Gregg, Jeffrey P., Stephens, Phil J., Frampton, Garrett M., Hegde, Priti S., Miller, Vincent A., Ross, Jeffrey S., Hartmaier, Ryan J., Huang, Shih-Min A., Sun, James X. · 2019 · The Journal of Molecular Diagnostics

Abstract

Microsatellite instability (MSI) is an important biomarker for predicting response to immune checkpoint inhibitor therapy, as emphasized by the recent checkpoint inhibitor approval for MSI-high (MSI-H) solid tumors. Herein, we describe and validate a novel method for determining MSI status from a next-generation sequencing comprehensive genomic profiling assay using formalin-fixed, paraffin-embedded samples. This method is 97% (65/67) concordant with current standards, PCR and immunohistochemistry. We further apply this method to >67,000 patient tumor samples to identify genes and pathways that are enriched in MSI-stable or MSI-H tumor groups. Data show that although rare in tumors other than colorectal and endometrial carcinomas, MSI-H samples are present in many tumor types. Furthermore, the large sample set revealed that MSI-H tumors selectively share alterations in genes across multiple common pathways, including WNT, phosphatidylinositol 3-kinase, and NOTCH. Last, MSI is sufficient, but not necessary, for a tumor to have elevated tumor mutation burden. Therefore, MSI can be determined from comprehensive genomic profiling with high accuracy, allowing for efficient MSI-H detection across all tumor types, especially those in which routine use of immunohistochemistry or PCR-based assays would be impractical because of a rare incidence of MSI. MSI-H tumors are enriched in alterations in specific signaling pathways, providing a rationale for investigating directed immune checkpoint inhibitor therapies in combination with pathway-targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jmoldx.2019.06.011

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 222

Metadata

Authors
Trabucco, S. E., Gowen, K., Maund, S. L., Sanford, E., Fabrizio, D. A., Hall, M. J., Yakirevich, E., Gregg, J. P., Stephens, P. J., Frampton, G. M., Hegde, P. S., Miller, V. A., Ross, J. S., Hartmaier, R. J., Huang, S.-M. A., & Sun, J. X.
Venue
The Journal of Molecular Diagnostics
Publisher
Elsevier BV
Published
2019-11
Volume
21
Issue
6
Pages
1053-1066
ISSN
1525-1578 (ISSN-L)
OpenAlex
W2969333588
Cited by
222
References
9
FWCI
17.21
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples. https://app.cochat.ai/papers/10.1016/j.jmoldx.2019.06.011
The paper
Trabucco, S. E., Gowen, K., Maund, S. L., Sanford, E., Fabrizio, D. A., Hall, M. J., Yakirevich, E., Gregg, J. P., Stephens, P. J., Frampton, G. M., Hegde, P. S., Miller, V. A., Ross, J. S., Hartmaier, R. J., Huang, S.-M. A., & Sun, J. X. (2019). A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples. The Journal of Molecular Diagnostics. https://doi.org/10.1016/j.jmoldx.2019.06.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.